SCHEMBL23970620

SCHEMBL23970620

CC(C)(C)OC(=O)c1c(CCCCCO)ccnc1Cl

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATR Q13535 1/20 0.40
TDP1 Q9NUW8 2/20 0.35
POLB P06746 1/20 0.34
CYP4F2 P78329 3/20 0.33
CYP4A11 Q02928 3/20 0.33
KDM4E B2RXH2 2/20 0.32
ALDH1A1 P00352 2/20 0.32
GLA P06280 2/20 0.32
GAA P10253 2/20 0.32
MAPT P10636 2/20 0.32
HPGD P15428 2/20 0.32
HIF1A Q16665 2/20 0.32
KMT2A Q03164 2/20 0.32
MEN1 O00255 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
THRB P10828 1/20 0.32
SSTR4 P31391 1/20 0.32
LMNA P02545 1/20 0.32
RXRA P19793 2/20 0.31
NR1H2 P55055 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23971324 0.86 TDP1 (0.35) ATRTDP1CYP4F2CYP4A11KDM4E
SCHEMBL23970566 0.85 SSTR4 (0.38) ATRTDP1CYP4F2CYP4A11KDM4E
SCHEMBL19778006 0.84 ATR (0.45) ATRTDP1POLBKDM4EALDH1A1
SCHEMBL29350439 0.84 ATR (0.45) ATRTDP1POLBKDM4EALDH1A1
SCHEMBL23970621 0.84 ATR (0.36) ATRTDP1POLBKDM4EALDH1A1
SCHEMBL25869369 0.83 ATR (0.46) ATRTDP1POLBKDM4EALDH1A1
SCHEMBL30158954 0.82 TDP1 (0.46) TDP1ALDH1A1MAPTHPGDKMT2A
SCHEMBL23971142 0.82 TDP1 (0.46) TDP1ALDH1A1MAPTHPGDKMT2A
SCHEMBL28950549 0.82 TDP1 (0.33) TDP1CYP4F2CYP4A11KDM4EALDH1A1
SCHEMBL23970619 0.81 CNR2 (0.35) TDP1CYP4F2CYP4A11KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115551862-B Macrocyclic inhibitors of peptidyl arginine deiminase 吉利德科学公司 2024-04-12 CN disclosed
EP-4143189-A1 MACROCYCLIC INHIBITORS OF PEPTIDYLARGININE DEIMINASES GILEAD SCIENCES, INC. (US) 2023-03-08 EP disclosed
US-20230002412-A1 INHIBITORS OF PEPTIDYLARGININE DEIMINASES GILEAD SCIENCES, INC. 2023-01-05 US disclosed
CN-115551862-A Macrocyclic inhibitors of peptidyl arginine deiminase 吉利德科学公司 2022-12-30 CN disclosed
WO-2021222353-A1 MACROCYCLIC INHIBITORS OF PEPTIDYLARGININE DEIMINASES GILEAD SCIENCES, INC. (US) 2021-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230002412-A1 INHIBITORS OF PEPTIDYLARGININE DEIMINASES PADI4, PADI2, PADI1 ATR 2569/4885TDP1 199/4885POLB 866/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.